- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| Di | New to The Street Signs Medicus Pharma Ltd. to Transformational 12-Part National Media Series Highlighting SkinJect and Teverelix Platforms | 333 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / April 7, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX), a precision-guided biotech and life sciences company advancing innovative therapeutic platforms, has entered... ► Artikel lesen | |
| Mo | Medicus Pharma Ltd: Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention | 302 | GlobeNewswire (Europe) | PHILADELPHIA, April 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| Mo | EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients | 2 | Benzinga.com | ||
| 01.04. | Medicus Pharma clarifies Phase 2 skin cancer study results | 2 | Investing.com | ||
| 01.04. | Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset | 2 | GlobeNewswire (USA) | ||
| 30.03. | Medicus Pharma Ltd: Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate | 176 | GlobeNewswire (Europe) | PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 26.03. | Medicus Pharma reports 80% response rate in skin cancer study | 3 | Investing.com | ||
| 26.03. | Medicus Pharma: Hautkrebsstudie zeigt 80 % Ansprechrate | 3 | Investing.com Deutsch | ||
| 26.03. | Medicus Pharma Ltd: Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan | 277 | GlobeNewswire (Europe) | PHILADELPHIA, March 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 26.03. | Medicus Pharma Ltd. GAAP EPS of $2.74 | 5 | Seeking Alpha | ||
| 25.03. | Medicus Pharma Ltd: Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update | 424 | ACCESS Newswire | Advances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 Programs PHILADELPHIA, PA / ACCESS Newswire / March 25, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX)... ► Artikel lesen | |
| 25.03. | Medicus Pharma Ltd. - 10-K, Annual Report | 3 | SEC Filings | ||
| 18.03. | Medicus Pharma to host fireside chat on SkinJect trial results | 3 | Investing.com | ||
| 18.03. | Medicus Pharma Ltd: Medicus Pharma To Discuss Positive Skinject Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst | 195 | ACCESS Newswire | Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, PA / ACCESS Newswire... ► Artikel lesen | |
| 16.03. | Medicus Pharma plant Webcast zu Studienergebnissen bei Basalzellkarzinom | 1 | Investing.com Deutsch | ||
| 16.03. | Medicus Pharma schedules webcast on basal cell carcinoma study | 1 | Investing.com | ||
| 16.03. | Medicus Pharma Ltd: Medicus Pharma Announces SkinJect Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 | 248 | GlobeNewswire (Europe) | Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16... ► Artikel lesen | |
| 10.03. | Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum | 399 | ACCESS Newswire | Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy PHILADELPHIA, PA / ACCESS Newswire / March 10, 2026 / Medicus... ► Artikel lesen | |
| 09.03. | Medicus Pharma Ltd: Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset | 263 | GlobeNewswire (Europe) | PHILADELPHIA, March 09, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 06.03. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 4 5 Weiter >>
86 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,355 | +0,43 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Chris Schott sieht für die Ziele des Pharmaherstellers Luft... ► Artikel lesen | |
| GILEAD SCIENCES | 121,40 | -0,02 % | BREAKING: Für bis zu 5 Milliarden Dollar! Gilead kauft Biotech-Firma aus München | Das Übernahme-Karussell im Biotech-Sektor dreht sich gefühlt von Woche zu Woche immer schneller. Erst am Ostermontag hat Neurocrine Biosciences die milliardenschwere Übernahme von Soleno Therapeutics... ► Artikel lesen | |
| ELI LILLY | 820,60 | +0,49 % | Eli Lilly erhält von der US-Behörde FDA eine Zulassung für das Abnehmmedikament Foundayo und geht damit weiter auf Angriffskurs gegen die Konkurrenz | Den US-Markt im Bereich von Abnehmmedikamenten konnte Eli Lilly im vergangenen Jahr bereits knapp erobern und damit Novo Nordisk zunächst hinter sich lassen. Doch zum Jahreswechsel wurden die Karten... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 380,45 | -0,34 % | Vertex Licenses Halozyme's Hypercon Technology For Use In Up To Three Drug Targets | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Halozyme Therapeutics (HALO) announced its subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with Vertex... ► Artikel lesen | |
| EYEPOINT | 12,000 | -0,83 % | EyePoint, Inc.: EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments | - Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 - - Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME -... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 2,800 | -1,41 % | Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 175,00 | +0,57 % | Ligand Pharmaceuticals: Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team | JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 171,55 | +1,33 % | Raymond James startet Coverage für Jazz Pharmaceuticals mit "Outperform" | ||
| UNITED THERAPEUTICS | 488,20 | -0,39 % | Raymond James stuft United Therapeutics mit "Outperform" ein - Kursziel 700 Dollar | ||
| OPKO HEALTH | 1,010 | +1,00 % | OPKO Health, Inc.: OPKO Health's ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 | WESTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial... ► Artikel lesen | |
| ROYALTY PHARMA | 40,730 | -1,32 % | Royalty Pharma, Johnson & Johnson Enter Co-funding Agreement To Advance Development Of JNJ-4804 | NEW BRUNSWICK (dpa-AFX) - Royalty Pharma plc (RPRX) announced a research and development co-funding agreement
with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,600 | -1,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 63,56 | -1,44 % | RBC Capital startet Coverage für BridgeBio Pharma mit "Outperform" und Kursziel 100 US-Dollar | ||
| TG THERAPEUTICS | 29,300 | -1,01 % | TG Therapeutics, Inc.: TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million | NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ("TG" or "the Company"), (NASDAQ: TGTX), today announced that it has entered into a new five-year, $750 million senior secured credit... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 8,340 | -5,50 % | Jefferies reiterates Corbus Pharmaceuticals stock rating at buy |
Das Unternehmen MEDICUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,441 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.